By Holly Magna, Ph.D., Nerac Analyst,
Originally Published: November 28, 2016
New developments in Immunotherapy continue to advance and show promising results in treatment of a variety of cancers. This article reviews some of the newly marketed therapies and some still in development, as well as their complications, risks and advantages.
Want to read the rest of the article? Fill out the form to download:Graphene: Quest for the Killer App
Related Posts
- 36New issue explores innovations in cancer treatments, graphene and drug safety updates. Read the full release here.
- 31By John Leavitt, Ph.D. Nerac Analyst Originally Published: August 12, 2014 In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt…
- 30By John Leavitt, Ph.D. Nerac Analyst Originally Published July 21, 2014 Such a protein appears to be described in a paper published in the journal Molecular Cancer Therapeutics in February 2014 by Heinz-Josef Lenz at the Keck School of Medicine of the University of Southern California in collaboration with colleagues at the University of Graz in…